TG Therapeutics Inc
🔔 Watch stock
Assessment
Our Rating
A journalistic assessment by our editorial team at the time of the deep dive — it rates the company, not the entry point. Not investment advice and not a solicitation to buy or sell.
The business works in principle, but one material question is open. As long as it stays open, our findings do not carry a quality verdict.
Why this colour
The value signal is real — a profitable, growing biotech with a clean balance sheet — but it deceives about the earnings quality: three quarters of the 2025 record profit is a one-time tax bonus, and almost all the revenue hangs on a single drug against Roche and Novartis. The case is a bet on the further commercialization of BRIUMVI and on the pipeline moving up, at a valuation that already prices in a lot, and with a freshly burdened balance sheet. If the operating profit grows into the valuation, the bet can pay off; if growth stalls, a high expectation meets a one-product business. The decision is yours.
What the thesis turns on
Assessment: Opportunities & Risks
TG Therapeutics is the rare profitable biotech in the value scanner: BRIUMVI, an anti-CD20 agent against multiple sclerosis, has driven revenue from $92 million to $606.9 million and pushed the company into the profit zone. But the 2025 record profit is three quarters a one-time tax bonus, about 98 percent of the business hangs on this one product, and the rivals are named Roche and Novartis. Positive equity and full coffers stand against a loan freshly increased to $750 million. Not investment advice.
Product & growth
BRIUMVI is growing impressively: net product revenue from $92.0 million (2023) to $606.9 million (2025), Q1 2026 alone $201.3 million (plus about 68 percent). The rare case of a profitable biotech with a clear product advantage (short infusion) in a growing MS segment.
Earnings quality
The record 2025 net income of $447.2 million consists of only $107.4 million from the business; $339.8 million is a one-time, non-cash tax bonus from the release of the valuation allowance on deferred taxes. The price-to-earnings ratio therefore looks cheaper than the operating result justifies.
Balance sheet & financing
Positive equity ($583.1 million, 31.03.2026), Altman-Z 6.15, about $572.8 million in cash — no distress. At the same time an accumulated deficit of about $1.1 billion, and in March 2026 the loan was increased from $250 million to $750 million (secured by all assets) with a simultaneous share buyback.
Concentration risk & competition
About 98 percent of revenue hangs on a single drug — "our only marketed product". In the MS market BRIUMVI competes with ocrelizumab (Roche, Ocrevus) and ofatumumab (Novartis, Kesimpta), both from significantly larger corporations; on the horizon possible new BTK inhibitors.
Valuation & momentum
Market value about $8.3 billion, P/S about 12, P/B about 15 — ambitious for a one-product business; Weinstein Stage 2, institutional accumulation, about 79 percent price gain over six months and a buy-leaning analyst consensus. Plenty of success is priced in (data as of July 8, 2026).
Worth Noting
Membership in the value scanner "Joel Greenblatt: Magic Formula" (not a warning scanner) was confirmed locally and live on July 14, 2026; TGTX shows up in 27 value, quality and momentum scanners, in no warning scanner.
All earnings and balance-sheet figures come from the verified annual report 10-K for 2025 (filed 27.02.2026) and the quarterly report 10-Q as of 31.03.2026; the 2025 net income contains a one-time income tax benefit of $339.8 million from the release of the valuation allowance on deferred taxes.
Price and valuation figures dated to July 8, 2026 (about $53.60, about 155 million shares); analyses are evergreen, daily prices are not a buy argument.
Stock Watch
This analysis is as of August 26, 2026. Stock Watch will tell you what's changed at TGTX since then.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 26.90 $ to 59.10 $ · Last price: 56.50 $ (As of: September 17, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/18/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Biotechnology
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| TG Therapeutics Inc TGTX | 8.7 | 20.3 | 59.7 | 82.4 | 17.0 | 87.3 | 76.3 |
| Vertex Pharmaceuticals Inc VRTX | 130.6 | 31.3 | 24.5 | 55.0 | 38.1 | 9.6 | 33.4 |
| Regeneron Pharmaceuticals Inc REGN | 82.0 | 19.9 | 13.1 | 44.5 | 20.7 | 1.0 | 35.5 |
| Moderna Inc MRNA | 62.7 | – | 4.6 | -66.0 | -131.1 | -39.2 | 532.3 |
| argenx NV ARGX | 61.9 | 38.1 | 34.2 | 59.1 | 32.0 | 89.6 | 30.9 |
| Revolution Medicines Inc RVMD | 40.9 | – | -9.7 | -174,708.6 | 0.0 | -100.0 | 338.3 |
| BeiGene, Ltd. ONC | 40.0 | 63.1 | 34.1 | 88.9 | 19.1 | 40.2 | 6.4 |
| Alnylam Pharmaceuticals Inc ALNY | 32.6 | 61.8 | 28.4 | 79.7 | 23.0 | 65.2 | -48.1 |
| Royalty Pharma Plc RPRX | 32.5 | 31.8 | 19.6 | 95.8 | 100.3 | 5.1 | 68.6 |
| Median of companies shown | 40.9 | 31.8 | 24.5 | 59.1 | 20.7 | 9.6 | 35.5 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 0 | -79 | -78 | -1.60 | -62 | 36 | 55 |
| 2017 | 0 | -119 | -118 | -1.91 | -94 | 67 | 97 |
| 2018 | 0 | -174 | -173 | -2.30 | -129 | 24 | 84 |
| 2019 | 0 | -169 | -173 | -1.96 | -133 | 39 | 163 |
| 2020 | 0 | -274 | -279 | -2.42 | -215 | 519 | 626 |
| 2021 | 7 | -345 | -348 | -2.63 | -296 | 237 | 380 |
| 2022 | 3 | -218 | -224 | -1.65 | -176 | 59 | 194 |
| 2023 | 234 | 21 | 13 | 0.09 | -31 | 161 | 330 |
| 2024 | 329 | 42 | 23 | 0.15 | -41 | 222 | 578 |
| 2025 | 616 | 123 | 447 | 2.77 | -25 | 648 | 1,063 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.15 | – | 108 | 146.00 | 21.60 | -26 | -26 |
| 2025: Q1 | 0.03 | – | 121 | 90.40 | 4.20 | -29 | -29 |
| 2025: Q2 | 0.17 | 301.90 | 141 | 92.10 | 20.00 | 7 | 7 |
| 2025: Q3 | 2.43 | 9,956.80 | 162 | 92.80 | 241.70 | -23 | -23 |
| 2025: Q4 | 0.14 | -0.70 | 193 | 78.00 | 12.00 | 20 | 20 |
| 2026: Q1 | 0.12 | 297.50 | 205 | 69.60 | 9.70 | -18 | -18 |
| 2026: Q2 | 0.05 | -70.60 | 240 | 70.30 | 3.20 | 39 | 39 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 32 of our scanner strategies — each hit links to the scanner.
Backtested Scanners
Growth
- Ben Bennett: Focus List
- Ben Bennett: Power Screen
- Dan Zanger: Leader
- EPS & Revenue Power
- EPS Acceleration
- High Revenue Growth
- Patrick Walker: 40, 40 Screen
- Quality Growth
- Ted Zhang: Super Stock Universe
- William O'Neil (CAN SLIM)
Quality & Balance Sheet
Breakout & Setup
Momentum & Trend
- 21-EMA Trend
- Above the 50- & 200-SMA
- High ADR (≥5%)
- Jeff Sun
- Mike Webster: Swing Trading List
- Oliver Kell: Strength on Down Day
- Qullamaggie: Trend Intensity (13/65)
- RS Leader (≥90)
- RS New Highs
- Richard Moglen: Top Performers 3/6 Month
- Stage 2 Leader
- Stan Weinstein: Checklist
- Stan Weinstein: Stage 2
Research
Risk & Weakness
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.95 | 0.70 – 1.32 | 960 | -65.7% | 4 |
| 12/31/2027 | 2.97 | 2.16 – 4.25 | 1,318 | 212.1% | 6 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Geprüft am 14.07.2026 gegen den Geschäftsbericht (10-K) 2025 (eingereicht 27.02.2026), den Geschäftsbericht 2024 (03.03.2025) sowie die vier jüngsten Quartalsberichte (10-Q) bis zum 31.03.2026. In den ausgewerteten SEC-Filings von TG Therapeutics findet sich kein wesentlicher KI-Bezug: Das Geschäft dreht sich vollständig um B-Zell-Erkrankungen und den anti-CD20-Antikörper BRIUMVI (ublituximab-xiiy) gegen Multiple Sklerose. „Artificial intelligence“ taucht ausschließlich als Risk-Factor-Thema auf — und dort nur in einer spekulativen „may adopt, use or incorporate“-Formulierung (das Unternehmen „könnte“ künftig KI in seine IT-Systeme aufnehmen) plus generischer Regulierungs- und Cybersecurity-Boilerplate (EU AI Act, „AI-washing“). Es gibt keine KI-Umsatzquelle, keinen belegten operativen KI-Einsatz im Geschäftsmodell und kein konkretes KI-Geschäftsrisiko fürs eigene Modell. Nach dem Kriterienkatalog bleibt es damit bei „Neutral“ (dokumentierter Negativ-Befund).
View the full file — quotes, sources, reviewed filings
„We, directly or through our third-party service providers, may adopt, use or incorporate AI technology and capabilities into information technology systems or software to help us operate our business more efficiently than existing industry tools."
Wir könnten — direkt oder über unsere externen Dienstleister — KI-Technologie und -Fähigkeiten in IT-Systeme oder Software aufnehmen, nutzen oder einbinden, um unser Geschäft effizienter zu betreiben als mit bestehenden Branchenwerkzeugen.
10-K · 2026-02-27 · View SEC filing
„TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases."
TG Therapeutics ist ein voll integriertes Biotechnologie-Unternehmen in der kommerziellen Phase, das sich auf die Akquisition, Entwicklung und Vermarktung neuartiger Behandlungen für B-Zell-Erkrankungen konzentriert.
10-K · 2026-02-27 · View SEC filing
Filings Reviewed: 10-Q 2026-05-06 · 10-Q 2025-11-05 · 10-Q 2025-08-08 · 10-Q 2025-05-09 · 10-K 2026-02-27 · 10-K 2025-03-03
Rated on July 14, 2026 · How the Rating Is Built
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 504.6%
- More than 10% revenue growth is expected for the coming year 30.4%
- Share count grows by less than 3% a year 6.0%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 83.3%
- Gross margin at 40% or higher and without meaningful erosion 83.7%
- Goodwill from acquisitions does not grow faster than revenue 0.0%
- Net debt below twice EBITDA 0.9 x EBITDA
- Operating cash flow covers the profits of the last three years -580 m
- Return on capital at 15% or higher, or up versus two years ago 13.6%
- Insiders hold at least 10% or are net buyers 7.5%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
5/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 152.1%
- Exp. sales growth 3Y > 5% 46.2%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 3.5%
- Net debt < 4x EBIT 1.0x
- EBIT positive, 10Y straight 3
- Max. EBIT decline < 50% 0.0%
- Return on equity > 15% 69.0%
- ROCE > 15% 13.6%
- Expected return > 10% 3.2%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 10, 2026 | Charney Laurence N | Director | Sell | 5,000 | 54.96 | 274,800 |
| Aug 7, 2026 | Charney Laurence N | Director | Other | 450 | 0.00 | – |
| Aug 7, 2026 | Charney Laurence N | Director | Other | 500 | 0.00 | – |
| Aug 6, 2026 | Charney Laurence N | Director | Other | 5,100 | 0.00 | – |
The company
About the Company
TG Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf die Akquisition, Entwicklung und Kommerzialisierung neuartiger Behandlungen für B-Zell-vermittelte Erkrankungen in den USA und international konzentriert.
- Employees
- 399
- Headquarters
- Morrisville, NC
- Address
- 3020 Carrington Mill Blvd., 27560 Morrisville, United States
- Phone
- 212 554 4484
- Website
- tgtherapeutics.com
- IPO Date
- 12/14/1995
- ISIN
- US88322Q1085
- Stock Split
- 100:5625 on 04/30/2012
- Stock Split
- 1:50 on 07/14/2011
Management
| Name | Title | Birth Year |
|---|---|---|
| Michael S. Weiss Esq., J.D. | Chairman, CEO & President | 1966 |
| Sean A. Power CPA | CFO, Corporate Secretary & Treasurer | 1982 |
| Jenna Bosco | Senior Vice President of Corporate Communications | – |
| Adam Waldman | Chief Commercialization Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
- 08/03/2026 TG THERAPEUTICS, INC. (TGTX): Results of Operations and Financial Condition; Financial Statements and Exhibits SEC ↗
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.